Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
Inclacumab was generally well tolerated in THRIVE-131
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research
The submission is supported by results from the Phase 3b APEX study
Subscribe To Our Newsletter & Stay Updated
